RANI
Rani Therapeutics Holdings, Inc.
There isn't enough reported data to score RANI yet.
RANI Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Under pressure | |
| Unavailable |
RANI's profitability and cash flow are currently under pressure. There isn't enough data to rate its revenue and balance sheet.
RANI PE Valuation
RANI has no meaningful PE right now: it lost money over the past year.
RANI Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect RANI's revenue to grow, with its earnings and profitability holding steady.
RANI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$0.78 | +$0.28 |
| Q2 2025 | -$0.90 | +$0.28 |
| Q1 2025 | -$0.98 | +$0.31 |
| Q4 2024 | -$1.05 | +$0.28 |
| Q3 2024 | -$1.06 | +$0.97 |
| Q2 2024 | -$1.18 | +$0.82 |
| Q1 2024 | -$1.29 | +$0.65 |
| Q4 2023 | -$1.33 | +$0.57 |
RANI is still losing money, but far less than before: $0.78 per share over the past year, against $2.03 at its worst in late 2023.
RANI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $1.7M | +893% |
| Q2 2021 | $2M | +3168% |
| Q1 2021 | $756K | +811% |
RANI's revenue has grown year over year for four quarters in a row: $2M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -540% | N/A |
| Q2 2026 | -517% | N/A |
| Q1 2026 | -488% | +6496 points |
| Q4 2025 | -584% | N/A |
| Q1 2025 | -6984% | N/A |
| Q2 2021 | -268% | +5382 points |
| Q1 2021 | -688% | +5799 points |
| Q4 2020 | -2354% | N/A |
RANI's operating margin was −540% last quarter, up 6444 points from the same quarter a year ago.
RANI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.9M | -$2.9M |
| Q2 2026 | -$9.1M | -$3.2M |
| Q1 2026 | -$6.5M | +$1.7M |
| Q4 2025 | $294K | +$9M |
| Q3 2025 | -$5.1M | +$3.5M |
| Q2 2025 | -$5.8M | +$3.3M |
| Q1 2025 | -$8.2M | +$1.2M |
| Q4 2024 | -$8.7M | +$4M |
RANI has burned cash in almost every quarter: −$23M over the past year, against −$28M the year before.
RANI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +6.3% | +11.8M shares |
| 1 year | +445% | +162M shares |
| 3 years | +713% | +175M shares |
| 5 years | +962% | +180M shares |
RANI has 199M diluted shares, up 445% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2022 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RANI Net Leverage
RANI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
RANI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.5 | Neutral |
| Stochastic | 5.7 | Oversold |
RANI's weekly RSI is 33 (neutral) and its Stochastic is 6 (oversold).
RANI PE vs Healthcare Sector
RANI has no meaningful PE right now: it lost money over the past year.
RANI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.66 | 20% below |
| 20 week MA | $0.75 | 29% below |
| 50 week MA | $0.98 | 46% below |
| 100 week MA | $1.02 | 48% below |
| 200 week MA | $2.40 | 78% below |
RANI is in a downtrend: it's below all five of its weekly moving averages, and 78% below its 200-week average.
RANI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $11.0 | $18.6 | +69% |
| 2022 | $18.6 | $6.05 | -67% |
| 2023 | $6.05 | $3.32 | -45% |
| 2024 | $3.32 | $1.42 | -57% |
| 2025 | $1.42 | $1.40 | -1.4% |
| 2026 YTD | $1.40 | $0.53 | -62% |
RANI has finished four years in a row lower, and it's down 62% so far in 2026.